Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

about

Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan Adjuvanted influenza vaccines

P2860

Q56525461-DE92E112-F6F7-4DFD-BD93-AC07152098FB Q57094841-D1D801C5-0A13-4398-9366-893D46CB1E91

P2860

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

Item

http://www.wikidata.org/entity/Q49739688

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

@en

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

@nl

type

Item

label

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

@en

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

@nl

prefLabel

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

@en

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

@nl

P1476

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

@en

P2093

Beatrice Astruc

http://www.w3.org/2001/XMLSchema#string

Mathilde Latreille-Barbier

http://www.w3.org/2001/XMLSchema#string

Nathalie Lavis

http://www.w3.org/2001/XMLSchema#string

Regine Rouzier

http://www.w3.org/2001/XMLSchema#string

Yves Donazzolo

http://www.w3.org/2001/XMLSchema#string

P2860

Influenza immunology evaluation and correlates of protection: a focus on vaccines.

Safety of the trivalent inactivated influenza vaccine among children: a population-based study.

Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine

Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.

Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use.

Effectiveness of the Brazilian influenza vaccination policy, a systematic review.

Immunosenescence: Influenza vaccination and the elderly.

Seasonality of influenza in Brazil: a traveling wave from the Amazon to the subtropics.

Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip.

Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies.

P304

2674-2677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2017.1363944

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28937844

http://www.w3.org/2001/XMLSchema#string

P921

Southern Hemisphere

P932

5703369

http://www.w3.org/2001/XMLSchema#string

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

about

P2860

P2860

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932